FDAnews Drug Daily Bulletin

ALERTNESX/EDS TREATMENTS REVIEWED BY NEUROINVESTMENT

June 6, 2006
A A

NeuroInvestment today announced the release of its June issue, which reviews novel analgesics being developed for the treatment of alertness and excessive daytime sleepiness (EDS). This category covers a broad range of pathology, ranging from the truly devastating effects of narcolepsy, to the widespread but modest effects of circadian rhythm disruption, due to shiftwork changes or jet lag.
Market Wire